- Citi Sticks To These Pharma Stocks Amid Trump’s 25% Tariff Plans NDTV Profit
- Top Indian drugmakers bank on bilateral talks for relief from planned US tariffs (February 20) Hindustan Times
- Indian drugmakers can retain US dominance even with tariffs, says industry body Reuters
- US tariff: ‘No major impact on pharma’ The Times of India
- Trump tariffs on pharma: Natco Pharma is scouting for acquisitions in US, RoW markets BusinessLine
Citi Sticks To These Pharma Stocks Amid Trump’s 25% Tariff Plans NDTV ProfitTop Indian drugmakers bank on bilateral talks for relief from planned US tariffs (February 20) Hindustan TimesIndian drugmakers can retain US dominance even with tariffs, says industry body ReutersUS tariff: ‘No major impact on pharma’ The Times of IndiaTrump tariffs on pharma: Natco Pharma is scouting for acquisitions in US, RoW markets BusinessLine Top stories – Google News
